MF
CLVS

Magnetar Financial’s Clovis Oncology, Inc. CLVS Stock Holding History

Magnetar Financial’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-29,946
Closed -$312K – 688
2019
Q4 		$312K Buy
+29,946
New +$218K 0.01% 435

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Magnetar Financial's CLVS Position: Q1 2020 in Review

Magnetar Financial sold out of Clovis Oncology, Inc. (CLVS) in Q1 2020, closing a stake of 29,946 shares — an estimated $312K sold.

Magnetar Financial first reported a position in CLVS in Q4 2019 and held it in 1 quarter. The position peaked at $312K in Q4 2019. 154 funds tracked by Wall St. Rank hold CLVS as of Q1 2020.

  • Magnetar Financial reported no remaining Clovis Oncology, Inc. position as of Q1 2020 after selling out during the quarter.
  • Magnetar Financial sold 29,946 Clovis Oncology, Inc. shares in Q1 2020, an estimated $312K.
  • Magnetar Financial first reported a position in Clovis Oncology, Inc. in Q4 2019 and held it in 1 quarter.
  • Magnetar Financial's Clovis Oncology, Inc. position peaked at $312K in Q4 2019.
  • 154 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2020.

Based on Magnetar Financial's 13F filing for Q1 2020, filed 15 May 2020.